Protagonist Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protagonist Therapeutics, Inc. (PTGX) on September 17, 2024. The report addresses corporate governance changes involving the Board of Directors and the Audit Committee.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters.
Material Changes
- Director Resignation: Daniel N. Swisher Jr. resigned from the Board of Directors and the Audit Committee, effective September 17, 2024.
- Board Size Reduction: The Board size was reduced from seven to six members.
- Committee Appointment: Sarah A. O'Dowd was appointed to the Audit Committee, effective September 19, 2024.
Management Commentary and Risks
Management stated that Mr. Swisher did not advise the Company of any disagreement regarding operations, policies, or practices. He will continue to serve as an advisor to the Company under an advisory agreement. No specific financial risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the terms of the advisory agreement with Daniel N. Swisher Jr.
- Confirm the updated composition of the Audit Committee following Sarah A. O'Dowd's appointment.
- Review the Company's most recent 10-Q or 10-K for current financial status, as this 8-K contains no financial data.